arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Viking Therapeutics, Inc.

VKTX

$25.77 ▼ -2.23 (-7.96%) at close

13 Visible periods

21 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Viking Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.9B

Dividend Yield —

Revenue Growth —

Op. Margin —

ROIC -61.6% ↘

FCF / Share $-2.47 ↘

Trailing P/E —

Price / Book 4.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Nov 5, 2026.

13-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$0.00

— —

Net Income Profit after all expenses

$-359.64M

↓ -227.1% —

FCF / Share Free cash flow per share

$-2.47

↓ -207.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
EPS Growth YoY (%)	-215.8% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-11.0% Weak ↑ Weak Improving Year-over-year change in earnings per share Optimal: > 10%	-1.1% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	-26.8% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-227.1% Weak ↓ Weak Declining Year-over-year change in net income	-28.0% Weak ↑ Weak Improving Year-over-year change in net income	-24.7% Weak ↑ Weak Improving Year-over-year change in net income	-25.2% Weak ↑ Weak Improving Year-over-year change in net income	-39.2% Weak ↓ Weak Declining Year-over-year change in net income	-53.2% Weak ↓ Weak Declining Year-over-year change in net income	-16.8% Weak ↓ Weak Declining Year-over-year change in net income	-7.2% Weak ↓ Weak Declining Year-over-year change in net income	-39.7% Weak ↓ Weak Declining Year-over-year change in net income	37.1% Excellent Excellent Year-over-year change in net income	-6.9% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-207.2% Weak ↓ Weak Declining Year-over-year change in free cash flow	-3.5% Weak ↑ Weak Improving Year-over-year change in free cash flow	-23.5% Weak Weak Year-over-year change in free cash flow	-2.2% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Effective Tax Rate (%) (%)	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—	—	—	—	—	—	—	—
FCF / Net Income (x)	0.77x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.80x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.70x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.55x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.96x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Return on Invested Capital (%)	-61.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-17.1% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-22.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-38.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-21.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-13.8% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-9.3% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-6.9% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-111.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-136.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-108.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	83.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-55.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-27.4% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-41.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-26.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-16.6% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-11.5% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-8.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-86.2% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-95.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-77.7% Weak Weak Operating profit relative to total assets Optimal: > 10%	-771.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-56.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-475%)	-12.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-183%)	-24.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-264%)	-47.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-416%)	-27.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-282%)	-16.2% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-208%)	-9.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-162%)	-7.4% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-149%)	-152.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1119%)	-183.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1321%)	-268.2% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-1888%)	98.9% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+559%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Interest Coverage (x)	—	—	—	—	—	—	—	-322.98x Weak Weak Operating income divided by interest expense Optimal: > 5x	-155.04x Weak Weak Operating income divided by interest expense Optimal: > 5x	—	—	—	—
Net Debt (USD)	$-165.81M	$-26.68M	$-55.52M	$-36.63M	$-26.37M	$-29.12M	$-8.38M	$-24.78M	$-8.99M	$-3.08M	$-768.55K	$-755.86K	$-179.62K

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Revenue per Share (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	—	—	—	—	—	—	—	—
Basic EPS, GAAP (USD)	$-3.19	$-1.01	$-0.91	$-0.90	$-0.71	—	—	—	—	—	—	—	—
Free Cash Flow per Share (USD)	$-2.47	$-0.81	$-0.78	$-0.63	$-0.62	—	—	—	—	—	—	—	—
Book Value per Share (USD)	$5.57	$7.89	$3.48	$1.86	$2.58	$3.34	$3.83	$4.15	$0.38	$0.39	$0.90	$-3.69	—
Tangible Book Value per Share (USD)	$5.57	$7.89	$3.48	$1.86	$2.58	$3.34	$3.83	$4.15	$0.38	$0.39	$0.90	$-3.69	—
Basic Weighted Avg Shares (shares)	112.67M	109.04M	94.35M	76.83M	77.20M	—	—	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Working Capital (USD)	$638.93M	$879.80M	$348.09M	$145.09M	$201.75M	$243.97M	$276.72M	$297.58M	$13.19M	$7.50M	$13.22M	$-21.74M	—
Total Equity (USD)	$639.06M	$880.28M	$348.42M	$145.32M	$201.88M	$244.34M	$277.12M	$297.75M	$13.46M	$8.04M	$8.72M	$-22.13M	—

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗	FY 2015 Dec 31, 2015 10-K ↗	FY 2014 Dec 31, 2014 10-K ↗	FY 2013 Dec 31, 2013 10-K ↗
Sales/Revenue/Turnover (USD)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	—
Net Income, GAAP (USD)	$-359.64M	$-109.96M	$-85.89M	$-68.87M	$-54.99M	$-39.49M	$-25.78M	$-22.06M	$-20.58M	$-14.73M	$-23.40M	$-21.88M	—
Operating Cash Flow (USD)	$-278.69M	$-87.79M	$-73.38M	$-48.40M	$-47.59M	$-21.78M	$-24.75M	$-18.75M	$-14.76M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 52 quarters

Viking Therapeutics, Inc.

Analytical Summary

13-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare VKTX with peers